Rohit Vanjani is a Senior Associate at General Atlantic and focuses on investments in the Healthcare sector. Before joining General Atlantic in 2018, Rohit was a Director and Senior Analyst in Equity Research at Guggenheim Securities where he focused on specialty and generic pharmaceuticals. Prior to that, he was a Therapeutics Analyst at Pura Vida Investments, a healthcare dedicated hedge fund. Earlier in his career, Rohit was a Senior Analyst at Oppenheimer & Co, and held prior research roles at Jefferies, UBS, and Leerink Swann, covering the biotechnology, managed care, hospitals, healthcare services, and specialty pharmaceuticals verticals. Rohit graduated with a B.S. in Biochemistry and Economics from the University of Michigan and an M.B.A. from the NYU Stern School of Business.